Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0780 phase III study in adults with heterozygous familial hypercholesterolaemia
2025-520520-17-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing LAROPROVSTAT with Placebo (2 arms). Primary endpoint: Relative change in LDL-C from baseline to 12 weeks. Planned start Sep 2025; status: authorised.
02
Drugs
laroprovstat
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2025-520520-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520520-17-00.